Skip to content
March 29, 2024

Equity.Guru

Investment information for the new generation

Search

NEJM

A study was published today in the New England Journal of Medicine which tested COMPASS Pathways’ (CMPS.Q) COMP360 psilocybin. The study is a phase II double-blind, randomized, controlled trial…